Emergent BioSolutions Inc. announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR). This modification is for BAT (Botulism Antitoxin Heptavalent), an antitoxin used in the treatment of symptomatic botulism.
The contract modification is an update to an existing 10-year contract with ASPR. It reinforces the U.S. government's ongoing commitment to stockpile BAT to help protect military and civilian populations against potential biological threats.
Emergent emphasizes its North American supply chain and capabilities in delivering life-saving solutions that safeguard public health and strengthen global emergency preparedness. The types and quantities of products maintained in a stockpile depend on the population requiring protection, available products, and government priorities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.